Viking Therapeutics posts Q1 2026 non-GAAP EPS -$1.37 on zero revenue, misses EPS estimates
Viking Therapeutics posts Q1 2026 non-GAAP EPS -$1.37 on zero revenue, misses EPS estimates
- Non-GAAP EPS declined 234% YoY in Q1 2026 to -$1.37, per the company's reported results.
- Q1 2026 revenue was $0, beating revenue estimates according to Viking Therapeutics' reported results.
- Q1 2026 net loss totaled $158.3 million, according to the company's update.
- Viking ended Q1 2026 with $603 million in cash, per its quarterly disclosure.
- VANQUISH Phase 3 obesity trials are now fully enrolled, according to Viking Therapeutics' Q1 2026 update.
- Company filed an IND for amylin agonist VK3019, further expanding its metabolic disease development pipeline.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.